Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000469146 | SCV000553000 | uncertain significance | Capillary malformation-arteriovenous malformation syndrome | 2024-11-18 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 6 of the RASA1 protein (p.Ala6Val). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with RASA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 411715). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002411513 | SCV002717297 | uncertain significance | Cardiovascular phenotype | 2022-10-07 | criteria provided, single submitter | clinical testing | The p.A6V variant (also known as c.17C>T), located in coding exon 1 of the RASA1 gene, results from a C to T substitution at nucleotide position 17. The alanine at codon 6 is replaced by valine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Ce |
RCV003431020 | SCV004159079 | uncertain significance | not provided | 2023-08-01 | criteria provided, single submitter | clinical testing | RASA1: PM2 |